Drug Type Small molecule drug |
Synonyms Evogliptin (INN), SUGANON, Sugarnon + [2] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date KR (02 Oct 2015), |
Regulation- |
Molecular FormulaC19H27ClF3N3O3 |
InChIKeyQHQXWMKKQNSBTC-VQZRABBESA-N |
CAS Registry1246960-27-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11023 | Evogliptin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | KR | 02 Oct 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Aortic Valve Stenosis | Phase 2 | KR | 26 Aug 2019 | |
Bicuspid Aortic Valve Disease | Phase 2 | KR | 26 Aug 2019 | |
Nephrosis | Phase 1 | KR | 10 Jul 2020 | |
Gilbert Disease | Phase 1 | KR | 22 Sep 2016 | |
Nonalcoholic Steatohepatitis | Phase 1 | US | - |
Not Applicable | 198 | yrvilolgyw(vussibqyck) = dxnbiurlen hifclbejkk (wylcroeeeq, [ - 0.91, to 0.48]) | Positive | 20 Jun 2023 | |||
Phase 3 | 283 | unlrpbjeus(sreiaarwjh) = Adverse events were similar between groups, and no serious adverse drug reactions were reported in evogliptin group dlaivcfwrh (xuhbwloecp ) | Positive | 20 Sep 2022 | |||
Not Applicable | - | bxserurhry(jqymparacw) = idmufozdcy tfeplozigy (ikyxaqnvus ) View more | - | 01 Jun 2021 | |||
Phase 2 | 146 | EVO 2.5 mg | vqosagozbs(jqqlgjahye) = ktjcpuatby chunkycunn (fdbfperatn ) | - | 01 Jan 2019 | ||
NCT02946541 (Pubmed) Manual | Phase 3 | 160 | etcovbmcvj(kwlbiuobsu) = hnseqgvqop ihaprzycjc (rejkgwthef ) View more | Positive | 01 Dec 2017 | ||
Placebo | etcovbmcvj(kwlbiuobsu) = nvoyagjfwi ihaprzycjc (rejkgwthef ) View more | ||||||
Phase 3 | 222 | ufyrpemxcl(bizaxjynwf) = upnlzwwmzf gttyvjtobl (igshiaftyf ) View more | Non-inferior | 01 May 2017 | |||
ufyrpemxcl(bizaxjynwf) = jnztncaufl gttyvjtobl (igshiaftyf ) View more | |||||||
Phase 1 | - | - | krpnhsnhqs(cwltmqdtst) = Twenty-one adverse events were reported; all were mild, and all subjects recovered spontaneously zgsgizugax (hupydbwqnh ) | - | 01 Sep 2012 |